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daBACKGROUND Current guidelines recommend cardiac rehabilitation (CR) in medically stable outpatients with heart
failure (HF); however, temporal trends and factors associated with CR referral among these patients in real-world
practice are not entirely known.
OBJECTIVES The purpose of this study was to assess proportional use, temporal trends, and factors associated with CR
referral at discharge among patients admitted with decompensated HF.
METHODS Using data from a national Get With the Guidelines–Heart Failure registry, we assessed the temporal trends
in CR referral among eligible patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection
fraction (HFpEF) at discharge after HF hospitalization between 2005 and 2014. On multivariable analysis, we also
assessed patient- and hospital-level characteristics that are associated with CR referral.
RESULTS Among 105,619 HF patients (48% with HFrEF, 52% with HFpEF), 10.4% (12.2% with HFrEF, 8.8% with
HFpEF) received CR referral at discharge. A signiﬁcant increase in CR referral rates was observed among both HFpEF and
HFrEF patients over the study period (ptrend <0.0001 for HFrEF, HFpEF, and overall). Compared with patients discharged
without CR referral, patients referred for CR were younger, predominantly men, and more likely to receive evidence-
based HF therapies at discharge. On multivariable analysis, younger age, fewer comorbid conditions, and in-hospital
procedures such as coronary artery bypass grafting, percutaneous coronary intervention, and cardiac valve surgery were
most strongly associated with CR referral.
CONCLUSIONS Only one-tenth of eligible HF patients received CR referral at discharge after hospitalization for HF. The
proportional use of CR referral is increasing over time among both HFrEF and HFpEF patients. Further strategies to
improve physician and patient awareness in regard to the beneﬁt of CR should be used to increase CR referral among
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AND ACRONYMS
CABG = coronary artery bypass
grafting
CAD = coronary artery disease
CMS = Centers for Medicare &
Medicaid Services
COPD = chronic obstructive
pulmonary disease
CR = cardiac rehabilitation
CVA = cerebrovascular
accident
EF = ejection fraction
GWTG-HF = Get With the
Guidelines–Heart Failure
HF = heart failure
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TIA = transient ischemic attack
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918O ver the past decade, heart failure(HF) has emerged as a major causeof morbidity, mortality, and health
care expenditures in the United States.
Currently, it affects >6.5 million Americans,
and >650,000 patients are newly diag-
nosed with HF each year (1). Despite sig-
niﬁcant advancements in pharmacological
therapies for HF management over the past
2 decades, HF continues to be a major cause
of hospitalizations in the Medicare age
group, with >1 million admissions annually
(2–11). Furthermore, it contributes to >43%
of annual Medicare spending (12).SEE PAGE 927Cardiac rehabilitation (CR) has been shown
to be effective in improving ﬁtness and
quality of life, and it reduces hospitalizations
among HF patients with reduced ejection
fraction (HFrEF) and HF patients with pre-
served ejection fraction (HFpEF) (13–22).
Current American College of Cardiology/
American Heart Association guidelines rec-ommend CR as a class IB recommendation for HFrEF
patients with New York Heart Failure Association class
II to III symptoms (23). In addition, the U.S. Centers for
Medicare & Medicaid Services (CMS) recently
approved coverage for CR for stable outpatients with
HFrEF (24). Despite the existing evidence and guide-
lines in favor of CR in patients with HF, the propor-
tional use of CR in this patient population and its
temporal trends in contemporary clinical practice
have not been evaluated to date (25). Therefore, we
used the Get With The Guidelines–Heart Failure
(GWTG-HF) database to determine the contemporary
proportional use, temporal trends, and major factors
associated with referral for CR at discharge among
patients admitted with acute decompensated HF (26).earch Institute; has received honoraria from the American Coll
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tional use of evidence-based HF therapies among pa-
tients with or without CR referral at discharge.
METHODS
DATA COLLECTION. The ongoing observational, pro-
spective GWTG-HF registry and quality improvement
program, initiated in January 2005 by the American
Heart Association, has been described in detail previ-
ously (26). Hospital participation is voluntary and in-
cludes various institutions from all U.S. geographic
regions, representing community hospitals and tertiary-
care referral centers. The registry enrolls adults hos-
pitalized with new or worsening HF as the primary
diagnosis or with signiﬁcant HF symptoms that devel-
oped during hospitalization for which HF was the pri-
mary discharge diagnosis. Data collected include
demographics; clinical characteristics; medical history;
admitting diagnosis; inpatient medical therapies and
procedures; ejection fraction (EF); hospital characteris-
tics; compliance with HF-related performance mea-
sures, including use of and contraindications for
evidence-based medical therapies; CR referrals; and
in-hospital outcomes. Referral to CR is recorded as yes,
no, not documented, or not applicable. If none of the
ﬁelds is ﬁlled out, then the ﬁeld is considered missing.
Participant hospitals use the point-of service,
interactive, Internet-based patient management tool
to submit clinical information of consecutive eligible
patients to the database and are required to comply
with local regulatory and privacy guidelines. In
addition, hospital personnel are trained to use
standardized deﬁnitions. Because data are primarily
collected for quality improvement purposes, all
sites are granted a waiver for informed consent
under the common rule; however, approval from the
local institutional review board is essential before
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919coordination center for the American Heart Asso-
ciation/American Stroke Association Get With The
Guidelines programs. Duke Clinical Research Institute
serves as the data analysis center under an agreement
to analyze the aggregate de-identiﬁed data for re-
search purposes. The Internet-based data entry sys-
tem includes edit checks to ensure the completeness
of the reported data. Data quality is monitored, and
only sites and variables with a high degree of com-
pleteness are included in analysis.
STUDY POPULATION. We identiﬁed 307,082 patients
with an HF-related diagnosis discharged from 414
GWTG-HF participating hospitals between January 1,
2005, and June 30, 2014, as the starting population
(hospitals that failed to report data on past medical
history >25% of the time or patients with missing sex
information were excluded). The following group of
patients (n ¼ 195,844; 70 sites) were excluded from
the analysis: patients who were not eligible for CR
(patients discharged to hospice or an acute care fa-
cility, those who left against medical advice, those
who died in the hospital, and those who had comfort
care measures) and patients who had missing data on
CR referral or were coded as “not applicable” for CR
referral. Patients with missing information on left
ventricular EF (n ¼ 4,880; 6 sites) or patients with
missing or undocumented discharge status (n ¼ 739)
were also excluded. This resulted in a ﬁnal sample
size of 105,619 patients from 338 hospitals. To eval-
uate for potential selection bias, we compared patient
and hospital characteristics of our included study
population with those of patients who were excluded
because of missing CR referral data. Compared with
those included in the analysis, patients excluded
because of missing CR referral data had similar de-
mographics and underwent a similar rate of in-
hospital procedures but received a proportionally
higher prescription of evidence-based medical ther-
apies for HF at discharge.
STATISTICAL ANALYSIS. Patient and hospital char-
acteristics between patients with and without a CR
referral were compared. We report percentages for
categorical variables and medians with 25th and 75th
percentiles for continuous variables. Categorical var-
iables were also compared with the Pearson chi-
square test if sample size was sufﬁcient; otherwise, a
Fisher exact test was used. Continuous variables were
also compared with Kruskal-Wallis tests. We used the
Cochran-Armitage test to assess temporal trends in CR
referral across the study period (2005 to 2014) in the
overall study population, as well as in the subgroups
of patients with HFrEF and HFpEF. Furthermore, we
analyzed and compared the proportional use of
evidence-based HF therapies at discharge betweenthe 2 groups using similar methodology as discussed
above. Finally, we performed multivariable logistic
regression analysis with backward selection to iden-
tify factors that were independently associated with
CR at discharge (in the overall population and for
patients with HFrEF and HFpEF). All regression
models included a temporal variable to account for
changes over time. A ﬁnal multivariable logistic
regression model with generalized estimating equa-
tions approach was used to account for within-
hospital clustering. Variables included in the initial
model included the following: demographics (age,
sex, race, insurance), medical history (ischemic his-
tory of HF, atrial ﬂutter/ﬁbrillation, anemia, cere-
brovascular accident/transient ischemic attack (CVA/
TIA), prior myocardial infarction (MI), hypertension,
hyperlipidemia, diabetes mellitus, peripheral vas-
cular disease, renal insufﬁciency, chronic obstructive
pulmonary disease, coronary artery disease [CAD],
smoking, cardiac resynchronization therapy with
deﬁbrillator, implantable cardioverter-deﬁbrillator),
laboratory values (left ventricular EF at admission,
systolic blood pressure, heart rate, sodium, blood
urea nitrogen at discharge), in-hospital procedures
(percutaneous coronary intervention [PCI] with
balloon angioplasty or stent, cardiac valve surgery,
coronary artery bypass grafting [CABG], cardiac re-
synchronization therapy with deﬁbrillator, place-
ment of an implantable cardioverter-deﬁbrillator),
and hospital characteristics (geographic region, hos-
pital type [teaching/nonteaching], number of beds,
and urban vs. rural location). We made assumptions
and used corresponding methods to address missing
data in this analysis. If a patient had an unknown
status of medical history or procedure in the hospital,
it was imputed to “no,” because we assumed the
hospital personnel did not ﬁll these portions when
none applied. When other patient characteristics or
laboratory test results were missing, multiple impu-
tation was used; 25 imputed datasets were generated
by use of fully conditional speciﬁcation methods.
Missing hospital characteristics were not imputed,
and patients without these data were excluded from
multivariable models (0.3% of sample). Final esti-
mates represent the combined results over the 25
imputations. Continuous variables were assessed
for their linear association with CR referral, and
spline transformations were applied when necessary.
Subgroup analyses were also performed to examine
referrals in CR, trends in referrals, and factors asso-
ciated with CR referrals among patients with HF who
did and did not have another potentially qualifying
indications for CR separately. For this analysis, the
study population was divided into 2 groups: if a
TABLE 1 Baseline Demographic and Clinical Characteristics in the
Overall Study Population and Stratiﬁed by CR Referral
Overall
(N ¼ 105,619)
CR Referral
(n ¼ 11,023)
No CR Referral
(n ¼ 94,596) p Value
Age, yrs 74 (62–83) 70 (59–80) 74 (62–83) <0.0001
Female 48 43 49 <0.0001
BMI, kg/m2 28 (24–34) 28 (24–34) 28 (24–34) <0.0001
Race <0.0001
White 70 64 71
Black 19 19 19
Hispanic 7 12 7
Asian 1 1 1
Other (includes UTD) 3 4 3
Insurance status <0.0001
Medicare 57 51 58
Medicaid 10 11 10
Other 27 31 27
None/not documented/UTD 5 8 5
EF (%) 40 (25–55) 35 (23–52) 40 (25–55) <0.0001
Comorbid conditions
Smoking 18 21 17 <0.0001
Hypertension 78 74 79 <0.0001
Hyperlipidemia 48 45 49 <0.0001
Diabetes 44 44 44 0.37
CAD 50 47 50 <0.0001
PAD 13 11 13 <0.0001
Prior MI 20 17 20 <0.0001
Prior PCI 12 13 12 0.0022
Prior CABG 15 15 15 0.66
CVA/TIA 15 11 15 <0.0001
COPD/asthma 31 27 32 <0.0001
Anemia 19 13 20 <0.0001
Dialysis 4 3 4 <0.0001
In-hospital procedures
ICD 4 4 4 0.08
CRT-D 3 3 3 0.11
Pacemaker 1 1 1 0.03
Coronary angiography 10 17 9 <0.0001
PCI with stent 1 3 1 <0.0001
CABG 1 2 0.4 <0.0001
Cardiac valve surgery 0.4 1 0.4 <0.0001
Hospital characteristics
Region <0.0001
West 13 17 12
South 32 49 30
Midwest 22 14 23
Northeast 33 19 35
Hospital type (teaching) 63 65 63 0.0003
Number of beds 408 (280–575) 394 (280–556) 410 (283–575) <0.0001
Values are median (interquartile range) or %.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease;
COPD ¼ chronic obstructive pulmonary disease; CR ¼ cardiac rehabilitation; CRT-D ¼ cardiac resynchronization
therapy-deﬁbrillator; CVA/TIA ¼ cerebrovascular accident/transient ischemic attack; EF ¼ ejection fraction;
ICD ¼ implantable cardioverter-deﬁbrillator; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease;
PCI ¼ percutaneous coronary intervention; UTD ¼ unable to determine.
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920patient had CABG, CABG/PCI undetermined, prior PCI,
or any of certain in-hospital procedures (PCI with
stent, cardiac valve surgery, CABG, PCI), they were
included in the “traditional CR indications group.”
The second group, the “no traditional CR indications
group,” comprised the remaining patients. Patients
missing medical history or information on in-hospital
procedures were excluded from this analysis. Analysis
of the trend of CR referral and factors associated with
CR referral were performed by similar statistical
methods as described above. Differences were con-
sidered statistically signiﬁcant at p < 0.05; all statis-
tical tests were 2-sided. SAS version 9.3 (SAS Institute
Inc., Cary, North Carolina) was used for all analyses.
RESULTS
Among 105,619 HF patients (48% with HFrEF, 52%
with HFpEF) eligible for CR, 10.4% (12.2% with
HFrEF, 8.8% with HFpEF) received CR referral at
discharge. Patient and hospital characteristics with
and without CR referral at discharge are shown in
Table 1. Compared with patients discharged without
CR referral, patients referred for CR were younger
(median [interquartile range] age: 70 [59 to 80] years
vs. 74 [62 to 83] years), were predominantly men (57%
vs. 51%), and had a lower burden of comorbidities, a
lower proportion of Medicare coverage, and a greater
proportional use of in-hospital procedures such as
coronary angiography, PCI with stent, and CABG.
There was signiﬁcant regional variability in the use of
CR referral compared with non-CR referral. Among
participating centers with CR, there was a higher
referral among southern centers (49%) than mid-
western centers (14%).
Table 2 summarizes the achievement and quality
measures by CR referral for the study population.
Among patients eligible for use of pharmacotherapies
for HF (mainly those in the HFrEF group), patients
referred to CR had greater proportional use of
evidence-based medical therapies at discharge,
including angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers and aldosterone an-
tagonists. Proportional use of inﬂuenza/pneumo-
coccal vaccination and a follow-up visit within less
than 7 days of discharge was also greater among pa-
tients referred for CR.
Select factors independently associated with CR
referral in the ﬁnal multivariable model are listed in
Table 3. Younger age and use of in-hospital pro-
cedures such as CABG, PCI with or without stent, and
cardiac valve surgery were most strongly associated
with CR referral. Comorbid conditions such as a his-
tory of hypertension, CVA/TIA, chronic obstructive
TABLE 2 Summary of Achievement and Quality Measures by CR Referral Among
Eligible Patients With Heart Failure in Study Population
Overall
(N ¼ 105,619)
CR Referral
(n ¼ 11,023)
No CR Referral
(n ¼ 94,596) p Value
Achievement measures at discharge
ACE-I/ARB 91 94 91 <0.0001
Beta blockers 95 96 95 <0.0001
Measurement of LV function 100 100 100 <0.0001
Post-discharge appointment for HF 18 21 17 <0.0001
Quality measures at discharge
Aldosterone antagonists 34 40 34 <0.0001
H-ISDN 26 27 26 0.37
Anticoagulation for AF 72 73 72 0.30
DVT prophylaxis 72 78 71 <0.0001
CRT-D/CRT-P placed or prescribed 46 48 46 0.23
ICD counseling or placed 50 51 50 0.16
Inﬂuenza vaccination 40 51 39 <0.0001
Pneumococcal vaccination 41 48 40 <0.0001
Follow-up visit within 7 days 68 72 67 <0.0001
Values are %.
ACE-I ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker;
CR ¼ cardiac rehabilitation; CRT-D ¼ cardiac resynchronization therapy-deﬁbrillator; CRT-P ¼ cardiac resynchro-
nization therapy-pacemaker; DVT ¼ deep venous thrombosis; H-ISDN ¼ hydralazine-isosorbide dinitrate;
ICD ¼ implantable cardioverter-deﬁbrillator; LV ¼ left ventricular.
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921pulmonary disease (COPD), anemia, higher EF, and
increased systolic blood pressure lowered the odds of
CR referral at discharge. In addition, women were less
likely to be referred to CR on unadjusted analysis
(odds ratio: 0.89; 95% conﬁdence interval: 0.85 to
0.93; p < 0.001), but this difference disappeared on
adjusted analysis (odds ratio: 0.97; 95% conﬁdence
interval: 0.94 to 1.01; p ¼ 0.11). Finally, hospital
characteristics including geographic location, aca-
demic status, and bed size were not associated with
CR referral.
Over the study period, we observed a signiﬁcant
increase in the proportion of CR referral in the overall
population (from 9.6% to 13.3%; ptrend <0.001)
(Figure 1). Among patients with HFrEF, there was a
temporal increase in CR referral (from 9.6% to 15.5%;
ptrend <0.001). The increase in CR referral among
patients with HFpEF was more modest during the
study period (from 9.6% to 11.6%; ptrend <0.001).
SUBGROUP ANALYSIS. Of the overall study popula-
tion (n ¼ 105,619), 35,078 HF patients were classiﬁed
into a traditional CR indications group and 65,573 in
the group with no traditional CR indications. The
proportion of CR referral was similar in both groups,
with no statistically signiﬁcant difference (10.1% vs.
10.1%). There was a modest but statistically signiﬁ-
cant increase in the proportion of patients referred to
CR in both groups over the study period (from 10.3%
to 13.0% in the traditional CR indications group,
ptrend <0.0001; from 9.3% to 12.1% in the group with
no traditional CR indications, ptrend <0.0001)
(Figure 2). Select factors associated with CR in the
group with no traditional CR indications are shown in
Table 4. On adjusted analysis, patients with a history
of hypertension, CVA/TIA, COPD, higher EF, and
higher systolic blood pressure were less likely to be
referred to CR, whereas patients admitted with HF
after year 2010 were more likely to be referred to CR.
There were no sex, ethnic, or regional variations
associated with CR referral in this subgroup.
DISCUSSION
In our study involving >100,000 patients admitted
with HF at 338 U.S. sites participating in GWTG-HF, we
observed several notable ﬁndings. First, there is un-
derutilization (10%) of CR among patients discharged
after HF hospitalization (Central Illustration). Second,
there is an increasing temporal trend in referral for CR
among these patients over the past decade, although
in absolute terms, referral rates remain quite low even
in the most recent year of the study period. Third, in-
hospital procedures such as CABG, PCI, and cardiac
valve procedures were strongly associated with CRreferral at discharge in hospitalized HF patients.
Finally, in subgroup analysis, rates or trends of
referral of CR were similar between patients with HF
who also had traditional indications for CR referral
(e.g., post-CABG/cardiac valve procedures, post-PCI,
post-acute coronary syndrome) and those without
such traditional indications.
Patients with HF often have reduced exercise
tolerance because of dyspnea and fatigue and expe-
rience worse quality of life with recurrent hospitali-
zations (16). Meta-analysis of several trials involving
both HFrEF and HFpEF patients has demonstrated
that CR improves ﬁtness and health-related quality of
life and reduces rehospitalizations (18,21). Despite
existing evidence and guideline-based recommenda-
tions in favor of CR, we observed a signiﬁcant un-
derutilization of CR at discharge among patients
hospitalized with HF. Approximately 10% of eligible
HF patients in the present study received a CR
referral at discharge. The patterns of CR referral in
our study involving HF patients are similar to those
for CAD patients but demonstrate even lower referral
for HF patients (approximately 10%) than for CAD
patients who present with acute or chronic coronary
syndromes and undergo revascularization procedures
(range: 40% to 85%) (27–29). To the best of our
knowledge, these are among the ﬁrst reported rates of
CR referral in HF patients in a real-world population.
Our study has several clinical implications. Despite
CR being a safe, effective therapy for HF patients, the
TABLE 3 Select Factors Associated With Cardiac Rehabilitation Referral at Discharge Among Overall Study Population With Heart Failure
Factor
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
Trend per year increase starting from 2010 1.15 (1.01–1.30) 0.0287 1.16 (1.02–1.32) 0.0194
Age >65 yrs (increase per 5 yrs) 0.95 (0.94–0.97) <0.0001 0.97 (0.95–0.98) <0.0001
Medical history
Smoking 1.17 (1.11–1.23) <0.0001 1.10 (1.04–1.16) 0.0003
Hypertension 0.91 (0.86–0.96) 0.0010 0.92 (0.87–0.98) 0.0049
CVA/TIA 0.92 (0.87–0.97) 0.0013 0.94 (0.90–0.99) 0.0268
COPD 0.95 (0.90–0.99) 0.0218 0.94 (0.89–0.99) 0.0112
Anemia 0.88 (0.83–0.94) 0.0002 0.92 (0.86–0.97) 0.0040
Ejection fraction (increase per 5%) 0.97 (0.96–0.98) <0.0001 0.98 (0.97–0.99) <0.0001
Systolic BP (increase per 5 mm Hg) 0.99 (0.98–0.99) <0.0001 0.99 (0.99–1.00) 0.0007
BUN >20 mg/dl but <50 mg/dl (increase per 5 mg/dl) 1.00 (0.99–1.02) 0.5666 1.02 (1.01–1.03) 0.0064
In-hospital procedures
Cardiac valve surgery 3.04 (1.99–4.64) <0.0001 1.76 (1.31–2.38) 0.0002
PCI with stent 2.50 (2.04–3.06) <0.0001 2.36 (1.91–2.90) <0.0001
PCI 2.22 (1.70–2.91) <0.0001 1.88 (1.46–2.42) <0.0001
CABG 4.12 (2.90–5.86) <0.0001 3.24 (2.40–4.37) <0.0001
BP ¼ blood pressure; BUN ¼ blood urea nitrogen; CABG ¼ coronary artery bypass grafting; CI ¼ conﬁdence interval; COPD ¼ chronic obstructive pulmonary disease;
CVA/TIA ¼ cerebrovascular accident/transient ischemic attack; OR ¼ odds ratio; PCI ¼ percutaneous coronary intervention.
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922design of well-deﬁned effective strategies for imple-
mentation of CR continues to pose a challenge in
clinical practice. A successful CR program starts with
referral of eligible HF patients for CR by health care
professionals who manage these patients in inpatient
settings. Our study highlights a signiﬁcant gap in the
contemporary clinical practice with respect to thisn CR Referral Among HF Patients at Hospital Discharge
2007 2008 2009
Admission Year
2010 2011 2012 2013 2014
Overall HFrEF HFpEF
eferral to cardiac rehabilitation (CR) among patients with heart failure
ection fraction (HFrEF), HF with preserved ejection fraction (HFpEF),
lation with HF for each year from 2005 to 2014 at 338 U.S. sites.key step. The reasons for low CR referral speciﬁcally
in the HF population have not been prospectively
elucidated thus far; however, multiple physician and
patient-level factors could be involved. Recent
studies have demonstrated that among physicians,
one of the most important factors inﬂuencing
whether they referred patients to CR was the degree
of the physician’s perceived beneﬁt of CR (30,31).
Lack of a mortality beneﬁt with CR among HF patients
and concerns regarding the safety of exertional
training among patients with recent HF decompen-
sation may inﬂuence health care providers to decide
against CR referral. In particular for HFpEF patients,
reduced CR referral may be explained by either
ignorance among physicians with regard to the ben-
eﬁts of CR in this patient population or the fact that
self-pay for CR is unrealistic given that this subgroup
of the HF population is not covered by Medicare re-
imbursements. In addition, several patient-level fac-
tors that can inﬂuence CR referral include patient
demographics, older age, lower socioeconomic status,
distance to travel to the CR center, insurance status,
higher copayments or pay from pocket, and higher
comorbidity burden, such as concomitant COPD,
stroke/TIA, or cognitive dysfunction that can limit
participation in CR. Furthermore, in our study, when
we evaluated the difference in proportional use of
evidence-based HF therapies among patients with or
without CR referral at discharge, we observed that
patients who did not receive CR referral were also less
likely to receive evidence-based pharmacotherapies
such as angiotensin-converting enzyme inhibitors or
FIGURE 2 Trends in CR Referral With or Without Traditional Indications
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indications for each year from 2005 to 2014 at 338 U.S. sites.
TABLE 4 Select Factors Associated With CR Referral in Patients With Heart Failure With
No Traditional Indication for CR
Factor
Unadjusted OR
(95% CI) p Value
Adjusted OR
(95% CI) p Value
Trend per year increase starting
from 2010
1.13 (1.01–1.26) 0.0384 1.13 (1.02–1.25) 0.0171
Age >65 yrs (increase per 5 yrs) 0.96 (0.95–0.98) <0.0001 0.97 (0.96–0.99) 0.0021
Medical history
Smoking 1.18 (1.10–1.26) <0.0001 1.11 (1.04–1.17) 0.0007
Hypertension 0.88 (0.82–0.95) 0.0004 0.92 (0.87–0.97) 0.0026
CVA/TIA 0.89 (0.83–0.95) 0.0005 0.92 (0.86–0.98) 0.0073
COPD 0.94 (0.89–1.00) 0.0532 0.94 (0.89–1.00) 0.0460
Anemia 0.86 (0.80–0.93) <0.0001 0.91 (0.85–0.97) 0.0041
Ejection fraction
(increase per 5%)
0.97 (0.96–0.98) <0.0001 0.98 (0.97–0.99) <0.0001
Systolic BP (increase per
5 mm Hg)
0.98 (0.98–0.99) <0.0001 0.99 (0.98–0.99) <0.0001
BUN >20 mg/dl but <50 mg/dl
(increase per 5 mg/dl)
1.00 (0.99–1.02) 0.6823 1.02 (1.00–1.03) 0.0468
CR ¼ cardiac rehabilitation; other abbreviations as in Table 3.
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923angiotensin receptor blockers and aldosterone an-
tagonists at discharge as deﬁned by performance
measures. It is plausible that patients deemed un-
suitable for CR referral were more sick and thus less
likely to tolerate these evidence-based HF medica-
tions. On the other hand, the presence of a CR referral
at discharge identiﬁes physicians who are more likely
to incorporate state-of-the-art evidence-based thera-
pies in management of HF patients. Taken together,
increased physician and patient awareness about the
beneﬁts of CR in HF may be an effective strategy to
increase CR referrals. In addition, equally important
for successful CR enrollment and participation are
systems and processes of care. These include efforts
to increase insurance coverage, reduce copays, and
expand the responsibilities to home health nurses,
physical therapists, and other health care providers to
widen the scope of home- and community-based CR.
Finally, with increasing use of mobile and Internet
services in the United States, innovative strategies
and new delivery systems such as telemedicine
should be adopted to motivate and improve CR
participation (32–34).
A somewhat encouraging ﬁnding in our study is an
increasing trend in the proportion of HF patients
referred for CR by approximately 40% in relative
terms over the past decade. Increasing data in favor
of the beneﬁcial effects and safety of CR in patients
with HF, guideline endorsements for CR referral in HF
patients, and improving insurance coverage might be
responsible for these improved trends. However, the
magnitude of the absolute increase in CR referral
among HF patients (4% in 9 years) is still small
compared with that reported among MI patients in a
recent study by Beatty et al. (35) (9% absolute in-
crease in 5 years). Recent initiatives and changes in
the U.S. health care system, such as accountable care
organizations under the new Affordable Care Act,
may play a role in improving access to CR by
removing some of the ﬁnancial constraints that
restrict minorities and lower socioeconomic classes
from participating in CR programs (36). Furthermore,
with recent U.S. CMS approval of CR for HFrEF pa-
tients in 2013, we might expect a major improvement
in referral trends for CR in elderly patients with HF
who have Medicare coverage. Finally, with pre-
liminary data supporting the beneﬁt of CR in HFpEF
patients, further trials on the effectiveness of CR in
this patient population and possibly a similar CMS
insurance coverage approval for CR among HFpEF
patients are needed to further improve the use of CR
in this patient group as well (18,21).
In our study, we also identiﬁed several factors
associated with CR referral on multivariable analysis.Younger age and in-hospital procedures such as PCI,
CABG, and cardiac valve surgeries were associated
with higher odds of CR referral. This is consistent
with strong guideline recommendations and insur-
ance coverage for CR among patients undergoing
these procedures. In contrast, factors such as a his-
tory of hypertension, COPD, or CVA/TIA and greater
EF were associated with a low likelihood for CR
referral. It may be that patients with a higher burden
CENTRAL ILLUSTRATION CR Referral in Heart Failure: Proportion and Predictors at Hospital Discharge
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This chart represents the percentage of patients who were admitted to a hospital with heart failure who were referred for cardiac rehabilitation (CR) at the time of
discharge from the hospital from 2005 to 2014 at 338 U.S. sites. Also depicted are positive and negative factors associated with CR referral at discharge that resulted in
higher and lower likelihoods of CR referral, respectively.
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924of comorbidities are perceived to be more intolerant
to exercise training by discharging physicians and
thus are less likely to be referred for CR.
Finally, it was not surprising that patients with in-
hospital procedures such as CABG, PCI, and valve
surgery had higher odds of being referred to CR than
those without such procedures, because these are
traditional indications for CR. To evaluate this
further, we also performed a subgroup analysis to
examine whether there were differences in CR
referral among patients with traditional indications
for CR (e.g., prior PCI/CABG or in-hospital PCI/CABG/
valve procedures) compared with those without such
indications among patients hospitalized for HF.
Interestingly, the rates and trends for CR referral
were very similar for those patients with and without
other potential qualifying indications for CR. These
ﬁndings strengthen our observation that the presence
of HF is one of the major contributors driving CR
referral in both groups of patients, because even after
the exclusion of patients with traditional indications
for CR, the rates of referral remained similar. In
addition, recent data from the American College of
Cardiology’s National Cardiovascular Data Registry
that examined factors associated with CR referral in
post-MI patients also identiﬁed the presence of HF asa negative predictor of CR referral, which provides
support for our ﬁndings (27).
STUDY LIMITATIONS. First, hospital participation in
the GWTG program is voluntary, and hence, the
overall proportion of eligible patients referred to CR
may not be the same in non–GWTG-participating
hospitals. In addition, even among participating
hospitals, we were not able to determine the referral
patterns of those hospitals with large amounts of
missing data. This limits the generalizability of our
ﬁndings. Second, because the GWTG-HF registry
captures only in-hospital data, we could not deter-
mine what proportion of patients were referred for
CR as outpatients, or among those referred for CR,
what proportion actually enrolled and participated in
CR. This is crucial, because prior studies involving
CR in post-MI patients have clearly demonstrated
that despite high rates of referral, fewer than one-
half of the patients who are referred for CR at the
time of hospital discharge actually have enrolled and
participated in CR at the end of 6-month follow-up
(37). Third, per Medicare, HF patients with
EF <35% and in New York Heart Association func-
tional class II to IV are eligible for coverage for CR. In
our study, HFrEF was deﬁned as HF patients with
PERSPECTIVES
COMPETENCY IN PRACTICE-BASED LEARNING: American
College of Cardiology/American Heart Association clinical practice
guidelines recommend cardiac rehabilitation to improve functional
status in patients with symptomatic heart failure and reduced
ejection fraction who are able to participate (Class I, Level of
Evidence: A), which may help prevent subsequent readmission
after discharge of patients hospitalized with heart failure.
TRANSLATIONAL OUTLOOK: Health economics studies are
needed to evaluate the cost, value, resource implications, and
impact on clinical outcomes of policy amendments that enhance
insurance reimbursement for cardiac rehabilitation services,
coupled with strategies to increase physician and patient
awareness of these services.
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925EF #40%. This leaves a gray zone of patients with EF
between 35% and 40% who might be considered as
under-referred for CR in our study and who do not
meet Medicare eligibility for CR. In addition, per
Medicare eligibility criteria, patients need to be sta-
ble as outpatients (New York Heart Association
functional class II to IV) for 6 weeks with no recent
hospitalizations/procedures during that period for
consideration for CR referral. This may explain in
part the under-referral to CR in our patient popula-
tion, because we focused on CR referral at the time
of hospital discharge. Fourth, several patient-level
variables such as education level, income, and so-
cioeconomic class, which can affect CR referral and
participation, were not collected in our study. Fifth,
data collection was dependent on the accuracy and
completeness of data abstraction from medical chart
review, particularly because eligibility for care met-
rics is based on documentation. Finally, we cannot
account for several measured and unmeasured con-
founding factors that could account for these asso-
ciations with CR referral.
CONCLUSIONS
Among patients hospitalized with HF, CR referral re-
mains low and has increased slowly over the past
decade. With escalating health care expenditures
related to HF hospitalizations, policy amendments toimprove insurance coverage or reimbursement and
better strategies to improve physician and patient
awareness about the beneﬁts of CR should be used to
increase CR referral among HF patients.
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